Ying Ma, Ph.D.
Ying Ma, PhD
Lecturer
School of pharmacy
Tianjin Medical University
22 Qixiangtai Road
Tianjin 300070
Phone: +86-13902146682
Email: maying@tmu.edu.cn
Education
B.A. Tianjin University of Technology, Tianjin, China, 2009
Ph.D. Tianjin Medical University, Tianjin, China, 2015
Postdoctoral Fellow Tianjin Medical University, Tianjin, China, 2015
Professional Experience
2015.07- Lecturer, School of pharmacy, Tianjin Medical University, Tianjin, China
Research Interest
CADD on the JMML and Diabetes
Publication
1.Wu J, Li W, Zheng Z, Lu X, Zhang H, Ma Y*, et al. Design, synthesis, biological evaluation, common feature pharmacophore model and molecular dynamics simulation studies of ethyl 4-(phenoxymethyl)-2-phenylthiazole-5-carboxylate as Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors. J Biomol Struct Dyn. 2021;39(4):1174-88.
2.Zhou L, Ma YC, Tang X, Li WY, Ma Y*, Wang RL. Identification of the potential dual inhibitor of protein tyrosine phosphatase sigma and leukocyte common antigen-related phosphatase by virtual screen, molecular dynamic simulations and post-analysis. J Biomol Struct Dyn. 2021;39(1):45-62.
3.Li WY, Ma Y*, Li HX, Lu XH, Du S, Ma YC, et al. Scaffold-based selective SHP2 inhibitors design using core hopping, molecular docking, biological evaluation and molecular simulation. Bioorg Chem. 2020;105:104391.
4.Liu WS, Yang B, Wang RR, Li WY, Ma YC, Zhou L, Ma Y*,et al. Design, synthesis and biological evaluation of pyridine derivatives as selective SHP2 inhibitors. Bioorg Chem. 2020;100:103875.
5.Ma YC, Yang B, Wang X, Zhou L, Li WY, Liu WS,Ma Y*,et al. Identification of novel inhibitor of protein tyrosine phosphatases delta: structure-based pharmacophore modeling, virtual screening, flexible docking, molecular dynamics simulation, and post-molecular dynamics analysis. J Biomol Struct Dyn.2020;38(15):4432-48.
6.Wu J, Sun Y, Zhou H,Ma Y*, Wang R. Design, synthesis, biological evaluation and molecular dynamics simulation studies of (R)-5-methylthiazolidin-4-One derivatives as megakaryocyte protein tyrosine phosphatase 2 (PTP-MEG2) inhibitors for the treatment of type 2 diabetes. J Biomol Struct Dyn. 2020;38(11):3156-65.
7.Wu JW, Zhang H, Li WY, Tang X, Li HL, Lu XH,Ma Y* et al. Design potential selective inhibitors for human leukocyte common antigen-related (PTP-LAR) with fragment replace approach. J Biomol Struct Dyn. 2020;38(18):5338-48.
8.Wu J, Sun Y, Zhou H, Ma Y*, Wang R*. Design, synthesis, biological evaluation and molecular dynamics simulation studies of (R)-5-methylthiazolidin-4-One derivatives as megakaryocyte protein tyrosine phosphatase 2 (PTP-MEG2) inhibitors for the treatment of type 2 diabetes. J Biomol Struct Dyn. 2019:1-10.
9.Wei-Ya L, Yu-Qing D, Yang-Chun M, Xin-Hua L, Ying M*, Wang R-L*. Exploring the cause of the inhibitor 4AX attaching to binding site disrupting protein tyrosine phosphatase 4A1 trimerization by molecular dynamic simulation. Journal of Biomolecular Structure and Dynamics. 2019;37(18):4840-51.
10.Wang R-R, Ma Y*, Du S, Li W-Y, Sun Y-Z, Zhou H, et al. Exploring the reason for increased activity of SHP2 caused by D61Y mutation through molecular dynamics. Comput Biol Chem. 2019;78:133-43.
11.Wang R-R, Liu W-S, Zhou L, Ma Y*, Wang R-L*. Probing the acting mode and advantages of RMC-4550 as an Src-homology 2 domain-containing protein tyrosine phosphatase (SHP2) inhibitor at molecular level through molecular docking and molecular dynamics. Journal of Biomolecular Structure and Dynamics. 2019:1-14.
12.Sun Y-Z, Wu J-W, Lu X-H, Ma Y*, Wang R-L*. Exploring the effect of aplidin on low molecular weight protein tyrosine phosphatase by molecular docking and molecular dynamic simulation study. Comput Biol Chem. 2019;83:107123.
13.Sun Y-Z, Chen X-B, Wang R-R, Li W-Y, Ma Y*. Exploring the effect of N308D mutation on protein tyrosine phosphatase-2 cause gain-of-function activity by a molecular dynamics study. Journal of Cellular Biochemistry. 2019;120(4):5949-61.
14.Liu W-S, Wang R-R, Li W-Y, Rong M, Liu C-L, Ma Y*, et al. Investigating the reason for loss-of-function of Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) caused by Y279C mutation through molecular dynamics simulation. Journal of Biomolecular Structure and Dynamics. 2019:1-12.
15.Liu W-S, Jin W-Y, Zhou L, Lu X-H, Li W-Y, Ma Y*, et al. Structure based design of selective SHP2 inhibitors by De novo design, synthesis and biological evaluation. Journal of Computer-Aided Molecular Design. 2019;33(8):759-74.
16.Liu WS, Wang RR, Sun YZ, Li WY, Li HL, Liu CL, Ma Y*, et al. Exploring the effect of inhibitor AKB‐9778 on VE‐PTP by molecular docking and molecular dynamics simulation. Journal of Cellular Biochemistry. 2019.
17.Du S, Yang B, Wang X, Li W-Y, Lu X-H, Zheng Z-H, Ma Y*, et al. Identification of potential leukocyte antigen-related protein (PTP-LAR) inhibitors through 3D QSAR pharmacophore-based virtual screening and molecular dynamics simulation. Journal of Biomolecular Structure and Dynamics. 2019:1-14.
18.Zhu Y, Han Y, Ma Y*, Yang P. ADME/toxicity prediction and antitumor activity of novel nitrogenous heterocyclic compounds designed by computer targeting of alkylglycerone phosphate synthase. Oncol Lett. 2018.
19.Ma Y, Li H-L, Chen X-B, Jin W-Y, Zhou H, Ma Y*, et al. 3D QSAR Pharmacophore Based Virtual Screening for Identification of Potential Inhibitors for CDC25B. Comput Biol Chem. 2018;73:1-12.
20.Li W-Y, Wei H-Y, Sun Y-Z, Zhou H, Ma Y*, Wang R-L*. Exploring the effect of E76K mutation on SHP2 cause gain-of-function activity by a molecular dynamics study. Journal of Cellular Biochemistry. 2018;119(12):9941-56.
21.Jin W-Y, Ma Y*, Li W-Y, Li H-L, Wang R-L. Scaffold-based novel SHP2 allosteric inhibitors design using Receptor-Ligand pharmacophore model, virtual screening and molecular dynamics. Comput Biol Chem. 2018;73:179-88.
22.Liu X, Jing Z, Jia W-Q, Wang S-Q, Ma Y*, Xu W-R, et al. Identification of novel PPARα/γ dual agonists by virtual screening, ADMET prediction and molecular dynamics simulations. Journal of Biomolecular Structure and Dynamics. 2017;36(11):2988-3002.
23.Li H-L, Ma Y*, Zheng C-J, Jin W-Y, Liu W-S, Wang R-L. Exploring the effect of D61G mutation on SHP2 cause gain of function activity by a molecular dynamics study. Journal of Biomolecular Structure and Dynamics. 2017;36(14):3856-68.
24.Ying Ma#, Hui-Yu Wei#, Yu-Ze Zhang, Wen-Yan Jin, Hong-Lian Li, Hui Zhou, Xian-Chao Cheng, and Run-Ling Wang*. Synthesis, bioactivity, 3D-QSAR studies of novel dibenzofuran derivatives as PTP-MEG2 inhibitors [J]. Oncotarget, 2017, 8(24); 38466-38481.
25.Hong-Lian Li#, Ying Ma#, Ying Ma,Yu Li, Xiu-Bo Chen, Wei-Li Dong, and Run-Ling Wang*.The design of novel inhibitors for treating cancer by targeting CDC25B through disruption of CDC25B-CDK2/Cyclin A interaction using computational approaches [J]. Oncotarget, 2017, 8 (20); 33225-33240.
Grant
Ongoing:
NSFT (18JCQNJC13700),2018/04-2021/03, the director,Design, synthesis, and bioactivity studies of SHP2 allosteric inhibitors.
The Science & Technology Development Fund of Tianjin Education Commission for Higher Education (2017KJ229), 2017/10-2020/09,the director,Design, synthesis, and bioactivity studies of SHP2 allosteric inhibitors;
NSFC(81773569),2019/01-2021/12, participant, Design, synthesis, and bioactivity studies of selective inhibitors ofE76K and D61G mutants of SHP2 implicated in JMML.
Completed:
NSFC(20972112), 2010/01-2012/12, participant, The design, synthesis, and biological study of antidiabetic drugs targeting PTP-1B, PPAR-α and PPAR-γ;
NSFC(81273361), 2013/01-2016/12,participant, The research on the selective protein tyrosine phosphatase SHP2 inhibitors.
NSFT(16JCZDJC32500),2016/04-2019/03, participant, The research on the selective SHP2 D61G、E76K inhibitors;
The International (Regional) Cooperation and Exchange Project of the National Natural Science Foundation of China(81611130090), 2016/01-2018/12, participant,Rational design, synthesis and activity screening of Shp2 inhibitors for treatment of leukemia.
